The U.S. Food and Drug Administration (FDA) has signaled a historic change in preclinical testing policy by moving toward reducing reliance on traditional animal models and encouraging the adoption of more human relevant methods. This evolution in regulatory thinking has important implications for biotech sponsors, preclinical CROs, and drug developers striving to accelerate safe and effective therapies to market.
Historically, animal testing has been a cornerstone of preclinical safety and toxicity evaluation. Recent FDA policy updates build on the 2022 FDA Modernization Act 2.0 and go further by encouraging the use of New Approach Methodologies (NAMs) — including organoid systems, computational models, and advanced cell based assays — that can often offer more human relevant biological insights than traditional in vivo studies.
Importantly, this shift does not mean that all animal testing will disappear overnight. Instead, the FDA’s evolving framework promotes scientific flexibility:
Hybrid testing strategies like this — sometimes called in vivitrosi — maximize scientific insight while reducing redundancy and improving the predictive relevance of preclinical data.
Several forces are converging that make this FDA shift a key trend in preclinical research:
1. Regulatory Momentum Toward Human Relevant Models
FDA’s roadmap and draft guidance document outline how human relevant systems — ranging from organ on a chip platforms to AI driven predictions — are becoming acceptable data sources for nonclinical safety assessments, especially for specific product classes like monoclonal antibodies.
2. Industry and Global Pressure to Innovate
Agencies beyond the FDA — including the European Medicines Agency (EMA) and NIH — are aligning with similar goals to reduce animal testing and adopt advanced methodologies, including computational and -human cell-based systems.
3. Practical Benefits for Sponsors
Using NAMs can support earlier insight into human biology, reduce costs, and shorten development timelines — all factors that are increasingly critical in a competitive drug development landscape.
Innovative platforms such as organoids, micro physiological systems (MPS), and in silico models are gaining traction because they often reflect human biology more accurately than species distant animal models. When these technologies are paired with artificial intelligence and machine learning, they enable sophisticated predictions of pharmacokinetics, toxicology, and drug response.
These tools are not just futuristic ideas; the FDA has already accepted some NAMs in select nonclinical contexts, and draft guidance shows a clear intention to expand their regulatory relevance.
The regulatory landscape is shifting toward complementary and flexible preclinical strategies that combine established and emerging methods. For sponsors, this means:
CROs that adapt quickly — developing both in vivo expertise and novel human relevant testing platforms — will be best positioned to support sponsors in this transition.
At InfinixBio, we recognize that drug development is entering a transformative era. Regulatory openness to NAMs, combined with advances in computational modeling and organoid technology, offers opportunities to enhance predictivity, safety insights, and translational relevance in preclinical programs.
Whether you are designing IN enabling studies, incorporating advanced PK/PD models, or integrating human relevant platforms into your workflow, our scientific team can help you leverage these evolving methodologies to accelerate development with confidence.
Contact InfinixBio to discuss how we can support your next preclinical program with both traditional and cutting-edge approaches tailored to regulatory expectations and scientific rigor.
Our experienced lab team is here to help. Reach out today to learn more.
Back to Blog
